Robert C Kaplan1, Garrett Strizich1, Chino Aneke-Nash1, Clara Dominguez-Islas2, Petra Bužková2, Howard Strickler1, Thomas Rohan1, Michael Pollak3, Lewis Kuller4, Jorge R Kizer5, Anne Cappola6, Christopher I Li7,8, Bruce M Psaty9, Anne Newman4. 1. Department of Epidemiology and Population Health and. 2. Department of Biostatistics and. 3. Department of Medicine and Oncology, McGill University, Montreal, Quebec, Canada H4A 3J1. 4. Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261. 5. Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461. 6. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104. 7. Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195. 8. Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109; and. 9. Cardiovascular Health Research Unit, Departments of Epidemiology and Health Services, University of Washington & Group Health Research Institute, Group Health Cooperative, Seattle, Washington 98101.
Abstract
Context: Multiple diseases may explain the association of the growth hormone/insulinlike growth factor-I (GH/IGF-I) axis with longevity. Objective: To relate circulating GH/IGF-I system protein levels with major health events. Design and Setting: This is a cohort study set in 4 US communities. Participants: Adults (N = 2268) 65 years and older free of diabetes and cardiovascular disease. Measurements: We assessed insulinlike growth factor binding protein-1 (IGFBP-1) and ghrelin in fasting and 2-hour oral glucose tolerance test (OGTT) blood samples, as well as fasting IGF-I and IGFBP-3. Hazard ratios for mortality and a composite outcome for first incident myocardial infarction, stroke, heart failure, hip fracture, or death were adjusted for sociodemographic, behavioral, and physiological covariates. Results: During 13,930 person-years of follow-up, 48.1% of individuals sustained one or more components of the composite outcome and 31.8% died. Versus the lowest quartiles, the highest quartiles of fasting and 2-hour ghrelin were associated with 27% higher (95% confidence interval [CI]: 6%, 53%) and 39% higher (95% CI: 14%, 71%) risks of the composite outcome, respectively. The highest quartile of 2-hour IGFBP-1 was associated with 35% higher (95% CI: 1%, 52%) risk of the composite end point. Similarly, higher mortality was significantly associated with higher fasting and 2-hour ghrelin levels and with 2-hour IGFBP-1 level. When examined together, 2-hour post-OGTT levels of IGFBP-1 and ghrelin tended to predict outcomes better than fasting levels. Conclusions: Circulating IGFBP-1 and ghrelin measured during an OGTT predicted major health events and death in older adults, which may explain the influence of the GH/IGF-I axis on lifespan and health.
Context: Multiple diseases may explain the association of the growth hormone/insulinlike growth factor-I (GH/IGF-I) axis with longevity. Objective: To relate circulating GH/IGF-I system protein levels with major health events. Design and Setting: This is a cohort study set in 4 US communities. Participants: Adults (N = 2268) 65 years and older free of diabetes and cardiovascular disease. Measurements: We assessed insulinlike growth factor binding protein-1 (IGFBP-1) and ghrelin in fasting and 2-hour oral glucose tolerance test (OGTT) blood samples, as well as fasting IGF-I and IGFBP-3. Hazard ratios for mortality and a composite outcome for first incident myocardial infarction, stroke, heart failure, hip fracture, or death were adjusted for sociodemographic, behavioral, and physiological covariates. Results: During 13,930 person-years of follow-up, 48.1% of individuals sustained one or more components of the composite outcome and 31.8% died. Versus the lowest quartiles, the highest quartiles of fasting and 2-hour ghrelin were associated with 27% higher (95% confidence interval [CI]: 6%, 53%) and 39% higher (95% CI: 14%, 71%) risks of the composite outcome, respectively. The highest quartile of 2-hour IGFBP-1 was associated with 35% higher (95% CI: 1%, 52%) risk of the composite end point. Similarly, higher mortality was significantly associated with higher fasting and 2-hour ghrelin levels and with 2-hour IGFBP-1 level. When examined together, 2-hour post-OGTT levels of IGFBP-1 and ghrelin tended to predict outcomes better than fasting levels. Conclusions: Circulating IGFBP-1 and ghrelin measured during an OGTT predicted major health events and death in older adults, which may explain the influence of the GH/IGF-I axis on lifespan and health.
Authors: D E Flanagan; R I G Holt; P C Owens; R J Cockington; V M Moore; J S Robinson; I F Godsland; D I W Phillips Journal: Acta Physiol (Oxf) Date: 2006-07 Impact factor: 6.311
Authors: Anne Marij G Burgers; Nienke R Biermasz; Jan W Schoones; Alberto M Pereira; Andrew G Renehan; Marcel Zwahlen; Matthias Egger; Olaf M Dekkers Journal: J Clin Endocrinol Metab Date: 2011-07-27 Impact factor: 5.958
Authors: Ian H de Boer; Gregory Levin; Cassianne Robinson-Cohen; Mary L Biggs; Andy N Hoofnagle; David S Siscovick; Bryan Kestenbaum Journal: Ann Intern Med Date: 2012-05-01 Impact factor: 25.391
Authors: Chino S Aneke-Nash; Xiaonan Xue; Qibin Qi; Mary L Biggs; Anne Cappola; Lewis Kuller; Michael Pollak; Bruce M Psaty; David Siscovick; Kenneth Mukamal; Howard D Strickler; Robert C Kaplan Journal: J Clin Endocrinol Metab Date: 2017-12-01 Impact factor: 5.958
Authors: T Li; Y Zhao; X Yang; Y Feng; Y Li; Y Wu; M Zhang; X Li; H Hu; J Zhang; L Yuan; Y Liu; X Sun; P Qin; C Chen; D Hu Journal: J Endocrinol Invest Date: 2022-05-21 Impact factor: 4.256
Authors: Jason L Sanders; Wensheng Guo; Ellen S O'Meara; Robert C Kaplan; Michael N Pollak; Traci M Bartz; Anne B Newman; Linda P Fried; Anne R Cappola Journal: J Gerontol A Biol Sci Med Sci Date: 2018-06-14 Impact factor: 6.053
Authors: Ping-Chung Kuo; Yue-Chiun Li; Anjar M Kusuma; Jason T C Tzen; Tsong-Long Hwang; Guan-Hong Ye; Mei-Lin Yang; Sheng-Yang Wang Journal: Antioxidants (Basel) Date: 2021-04-13